Market Performance - The medical services sector increased by 2.52% on February 3, with Norsig leading the gains [1] - The Shanghai Composite Index closed at 4067.74, up by 1.29%, while the Shenzhen Component Index closed at 14127.1, up by 2.19% [1] Top Gainers in Medical Services - Norsig (301333) closed at 78.98, up by 8.76% with a trading volume of 43,200 shares and a transaction value of 332 million [1] - Yinos (688710) closed at 61.07, up by 7.52% with a trading volume of 17,400 shares and a transaction value of 10.4 million [1] - Dean Diagnostics (300244) closed at 24.73, up by 6.69% with a trading volume of 447,200 shares and a transaction value of 1.084 billion [1] Market Capital Flow - The medical services sector saw a net inflow of 506 million from institutional investors, while retail investors experienced a net outflow of 4.12 billion [2][3] - The top stocks with significant institutional inflows included Tiger Medical (300347) with 103 million and Meinian Health (002044) with 86 million [3] Stock Performance Overview - The stock performance of various companies in the medical services sector showed a mix of gains and losses, with notable declines in stocks like Haocen Medical (002622) down by 1.97% [2] - The trading volume and transaction values varied significantly across different companies, indicating diverse investor interest [2]

Group 1 - The core viewpoint of the news is that Hongbo Pharmaceutical's stock has increased by 5.14%, reaching a price of 48.85 CNY per share, with a trading volume of 503 million CNY and a turnover rate of 8.46%, resulting in a total market capitalization of 6.819 billion CNY [1] - Hongbo Pharmaceutical, established on December 14, 2007, and listed on November 1, 2022, is located in Shanghai and focuses on drug discovery, pharmaceutical process research and development, and the commercial production of active pharmaceutical ingredients. The revenue composition is as follows: drug discovery 52.67%, commercial production 35.00%, process research and development 8.10%, and others 4.23% [1] Group 2 - Longcheng Fund's Longcheng Consumption Value Mixed A Fund (200006) is among the top ten circulating shareholders of Hongbo Pharmaceutical, holding 1.6009 million shares, unchanged from the previous period, representing 2.08% of circulating shares, with an estimated floating profit of approximately 3.8262 million CNY [2] - The Longcheng Consumption Value Mixed A Fund has a total scale of 474 million CNY, with a year-to-date return of 8.38%, ranking 925 out of 8874 in its category, and a one-year return of 26.19%, ranking 4175 out of 8124 [2] Group 3 - The fund manager of Longcheng Consumption Value Mixed A Fund is Long Yufei, who has been in the position for 8 years and 111 days, managing assets totaling 704 million CNY, with the best fund return during his tenure being 61.42% and the worst being -8.9% [3] Group 4 - Longcheng Consumption Value Mixed A Fund reduced its holdings in Hongbo Pharmaceutical by 100,000 shares in the fourth quarter, now holding 1.5009 million shares, which accounts for 6.37% of the fund's net value, making it the sixth-largest holding [4]

Investment Rating - The investment rating for the healthcare industry is "Positive" and maintained [14] Core Insights - The funding levels for Chinese innovative pharmaceutical companies are increasing, leading to a gradual improvement in the research and development (R&D) investment sentiment within the industry. This is expected to usher in a new cycle of prosperity for the innovative drug industry chain [5][12] - The trend of external business development (BD) is likely to benefit the domestic early-stage research industry significantly, as new business models allow early-stage projects to become tradable and monetizable assets, enhancing R&D investment returns [13] Summary by Sections Innovative Chain Development Review - Before 2020, multiple factors converged to initiate a significant rise in China's innovative drug sector, leading to the rapid development of the innovative chain, including CXO and life sciences services [10][30] - From 2020 to the first half of 2022, the global public health crisis accelerated capital inflow into the biopharmaceutical sector, resulting in high demand and a leap in the innovative chain segment, which also triggered a wave of IPOs and substantial supply-side expansion [10][39] - The second half of 2022 to 2024 saw a transition from a heated to a cooling phase, with a significant shift in supply-demand dynamics leading to industry internal competition and pressure on revenues and profit margins [10][54][57] Improvement in R&D Investment Sentiment - Starting from 2025, the R&D investment sentiment in China's innovative drug sector is expected to improve, with companies experiencing increased funding levels. The total amount raised through IPOs and additional offerings in 2025 is projected to reach 201.5 billion yuan, a 145% year-on-year increase [11][62] - The potential milestone payments from external BD are expected to reach 880.5 billion yuan in 2025, marking a 185.9% year-on-year increase, indicating a robust funding environment for innovative drug companies [11] Benefits to Early-stage Research Industry - The new external BD business model enhances the R&D investment return rates for Chinese innovative drug companies, thereby increasing their willingness to invest in R&D [11][13] - The early-stage research industry, including drug discovery CROs and clinical trial services, is expected to benefit significantly from the external BD trend, with leading companies in these segments poised for rapid growth [13]

Investment Rating - The industry rating is neutral, indicating that the overall return is expected to be between -5% and 5% relative to the CSI 300 index over the next six months [9]. Core Insights - Sarepta's gene therapy Elevidys has shown positive results in its Phase 3 clinical trial, maintaining higher than baseline scores in the North Star Ambulatory Assessment (NSAA) after three years in patients treated at an average age of 9 [5]. - The pharmaceutical sector experienced a decline of 1.11% on January 27, 2025, underperforming the CSI 300 index by 1.08 percentage points, ranking 27th among 31 sub-industries [4]. - Among sub-industries, other biological products (+0.13%) and in vitro diagnostics (-0.07%) performed well, while vaccines (-3.55%) and offline pharmacies (-2.69%) lagged [4]. Sub-industry Summary - Chemical Pharmaceuticals: No rating [3] - Traditional Chinese Medicine: No rating [3] - Biopharmaceuticals II: Neutral [3] - Other Pharmaceutical Industries: Neutral [3]

Core Viewpoint - Hongbo Pharmaceutical (301230.SZ) expects a net profit attributable to shareholders of 31.2 million to 38.1 million yuan for 2025, representing a year-on-year growth of 82.64% to 123.03% [1] Group 1: Financial Performance - The net profit excluding non-recurring gains and losses is projected to be between 20.9 million and 25.6 million yuan, indicating a significant year-on-year increase of 321.59% to 416.40% [1] - Non-recurring gains and losses are estimated to impact net profit by approximately 12 million yuan, primarily from project subsidies and investment income [1] Group 2: Business Development - The company continues to deepen its main business layout centered on "drug design as the core driver and one-stop service as the strategic leader," leading to a positive overall operational outlook for 2025 [1] - Revenue from drug discovery, process research and development, and commercial production has all seen year-on-year growth [1] - The capacity utilization rates of its wholly-owned subsidiaries, Shanghai Hongbo Shangyi Pharmaceutical Technology Co., Ltd. and Chengdu Hongbo Zhiyuan Pharmaceutical Technology Co., Ltd., have improved compared to the previous year [1] Group 3: Strategic Initiatives - The company has enhanced platform construction and continuously improved its industry chain service system, significantly boosting its one-stop comprehensive service capability from new drug discovery to commercial production [1] - These efforts have further consolidated the company's strategic competitive advantage [1]

Core Viewpoint - Hongbo Pharmaceutical (301230) forecasts a net profit attributable to shareholders of 31.2 million to 38.1 million yuan for 2025, representing a year-on-year growth of 82.64% to 123.03% [1] Group 1: Business Performance - The company has continuously deepened its main business layout and actively implemented its annual operating plan, resulting in a favorable overall business situation for 2025 [1] - Revenue from drug discovery, process research and development, and commercial production has all achieved year-on-year growth [1] Group 2: Operational Efficiency - The capacity utilization rates of its wholly-owned subsidiaries, Shanghai Hongbo Shangyi Pharmaceutical Technology Co., Ltd. and Chengdu Hongbo Zhiyuan Pharmaceutical Technology Co., Ltd., have improved to varying degrees compared to the previous year [1] - The company has enhanced operational efficiency through refined management and optimized resource allocation [1] Group 3: Strategic Development - Hongbo Pharmaceutical has strengthened platform construction and continuously improved its industrial chain service system [1] - The company has significantly enhanced its one-stop comprehensive service capability from new drug discovery to commercial production, further consolidating its strategic competitive advantage [1]

Core Viewpoint - Hongbo Pharmaceutical announced an expected net profit for the year 2025, projecting between 31.2 million to 38.1 million yuan, representing a growth of 82.64% to 123.03% compared to the previous year's net profit of 17.08 million yuan [1] Financial Performance - The projected net profit for 2025 is estimated to be between 31.2 million yuan and 38.1 million yuan [1] - This represents a significant increase of 82.64% to 123.03% from the previous year's net profit of 17.08 million yuan [1]

新京报贝壳财经讯 1月27日，泓博医药公告，预计2025年度归属于上市公司股东的净利润为3120万元～ 3810万元，同比增长82.64%～123.03%。扣除非经常性损益后的净利润为2090万元～2560万元，同比增 长321.59%～416.40%。报告期内，公司围绕"以药物设计为核心驱动、以一站式服务为战略主导"的发 展定位持续深化主营业务布局，积极落实年度经营计划，2025年整体经营态势良好。 ...

证券代码：301230 证券简称：泓博医药 公告编号：2026-004 上海泓博智源医药股份有限公司 2025年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一、本期业绩预告情况 1、业绩预告期间：2025 年 1 月 1 日至 2025 年 12 月 31 日。 2、业绩预告情况：预计净利润为正值且属于同向上升 50%以上情形 （1）以区间数进行业绩预告的 二、与会计师事务所沟通情况 单位：万元 项 目 本报告期 上年同期 归属于上市公司股 东的净利润 3,120 ～ 3,810 比上年同期 1,708.32 增长 82.64% ～ 123.03% 扣除非经常性损益 后的净利润 2,090 ～ 2,560 比上年同期 495.74 增长 321.59% ～ 416.40% 三、业绩变动原因说明 1、报告期内，公司围绕"以药物设计为核心驱动、以一站式服务为战略主导"的发 展定位持续深化主营业务布局，积极落实年度经营计划，2025 年整体经营态势良好。药物 发现、工艺研究与开发、商业化生产各业务板块营业收入均实现同比增长。两家全资子公 司上海泓博尚 ...

Group 1 - The core viewpoint of the news is that Hongbo Pharmaceutical has shown significant financial performance and trading activity, with a notable increase in revenue and net profit year-on-year [1][2][3] Group 2 - As of January 26, Hongbo Pharmaceutical's stock price increased by 1.64%, with a trading volume of 928 million yuan [1] - The financing buy-in amount on January 26 was 91.54 million yuan, while the financing repayment was 83.11 million yuan, resulting in a net financing buy of 8.42 million yuan [1] - The total balance of margin trading for Hongbo Pharmaceutical reached 388 million yuan, with the financing balance accounting for 5.53% of the circulating market value, indicating a high level compared to the past year [1] Group 3 - For the fiscal year ending September 30, 2025, Hongbo Pharmaceutical achieved an operating income of 514 million yuan, representing a year-on-year growth of 31.43% [2] - The net profit attributable to the parent company was approximately 34.75 million yuan, reflecting a substantial increase of 127.96% compared to the previous year [2] Group 4 - Since its A-share listing, Hongbo Pharmaceutical has distributed a total of 156 million yuan in dividends [3] - As of September 30, 2025, the number of shareholders was 14,000, a decrease of 1.34% from the previous period, while the average circulating shares per person increased by 1.36% to 8,960 shares [2][3]